However, AML and MDS patients with TP53 mutations show a better response to DAC than those with wild-type (WT) TP53, a typical tumor suppressor gene, making it difficult to explain the therapeutic effect of HMAs in terms of tumor suppressor gene activation15. This evidence concerns the gene TP53 and myelodysplastic syndrome.